Key result
Moderate-intensity statin plus ezetimibe matches high-intensity statin monotherapy for major cardiovascular events.
Why the study?
Does moderate-intensity statin with ezetimibe combination therapy reduce cardiovascular death, major cardiovascular events, or non-fatal stroke in patients with diabetes and ASCVD compared to high-intensity statin monotherapy?
RCT (n=1,398)
randomized
Does moderate-intensity statin with ezetimibe combination therapy reduce cardiovascular death, major cardiovascular events, or non-fatal stroke in patients with diabetes and ASCVD compared to high-intensity statin monotherapy?
Answers are grounded in this paper and cite their sources.
In patients with diabetes and ASCVD, moderate-intensity statin plus ezetimibe yields comparable cardiovascular outcomes to high-intensity statin monotherapy, with better tolerability and higher rates of LDL-C target achievement.
AIMS: This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy vs. high-intensity statin monotherapy among patients with diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD). METHODS AND RESULTS: This was a pre-specified, stratified subgroup analysis of the DM cohort in the RACING trial. The primary outcome was a 3-year composite of cardiovascular death, major cardiovascular events, or non-fatal stroke. Among total patients, 1398 (37.0%) had DM at baseline. The incidence of the primary outcome was 10.0% and 11.3% among patients with DM randomized to ezetimibe combination therapy vs. high-intensity statin monotherapy (hazard ratio: 0.89; 95% confidence interval: 0.64-1.22; P = 0.460). Intolerance-related discontinuation or dose reduction of the study drug was observed in 5.2% and 8.7% of patients in each group, respectively (P = 0.014). LDL cholesterol levels <70 mg/dL at 1, 2, and 3 years were observed in 81.0%, 83.1%, and 79.9% of patients in the ezetimibe combination therapy group, and 64.1%, 70.2%, and 66.8% of patients in the high-intensity statin monotherapy group (all P < 0.001). In the total population, no significant interactions were found between DM status and therapy regarding primary outcome, intolerance-related discontinuation or dose reduction, and the proportion of patients with LDL cholesterol levels <70 mg/dL. CONCLUSION: Ezetimibe combination therapy effects observed in the RACING trial population are preserved among patients with DM. This study supports moderate-intensity statin with ezetimibe combination therapy as a suitable alternative to high-intensity statins if the latter cannot be tolerated, or further reduction in LDL cholesterol is required among patients with DM and ASCVD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, Identifier:NCT03044665.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) conducted an RCT in Diabetes mellitus and atherosclerotic cardiovascular disease (n=1,398). Moderate-intensity statin with ezetimibe vs. High-intensity statin monotherapy was evaluated on 3-year composite of cardiovascular death, major cardiovascular events, or non-fatal stroke (HR 0.89, 95% CI 0.64-1.22, p=0.460). Moderate-intensity statin with ezetimibe was comparable to high-intensity statin for cardiovascular death, major cardiovascular events, or non-fatal stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: